Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period

Ads

You May Also Like

VBL Therapeutics to Present Today at the 2016 BIO International Convention

Dror Harats, CEO will discuss ASCO newly-reported VB-111 clinical data in Ovarian Cancer and ...

ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights

-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to ...